Oncoslice: Cancer Diagnostic Platform
Oncoslice: Cancer Diagnostic Platform
Embedded Files
Goal: Develop a device to screen cancer drug combination on live patient tumor samples.
Project Background Information
Project Background Information
Current models for cancer drug efficacy evaluation do not properly mimic the complexity of the human body. Drugs are meant to be delivered to patients and yet they are tested on systems that are either animal or cell culture. These two models have great value in early and late research stages, but they lack the complete/intact and highly variable tumor microenvironment from an individual patient.
Skills
Skills
Image data analysis with Matlab/Python/Excel/ImageJ
Patient collaboration and sample handling
Medical device manufacturing using CO2 laser cutting
Aseptic cell culture
Timeline
Timeline
May 2019 - August 2021
Collaborators
Collaborators
PI: Albert Folch
Post-doc: Lisa Horowitz
Device Overview
Device Overview
Utilized CO2 laser cut/raster and chemical solvent bonding process to produce leakproof platform with standardized channel geometry
Testing Overview
Testing Overview
Glioma xenografts (mouse) for device characterization and validation studies, patient studies performed with glioblastoma multiforme, colorectal liver metastasis and pancreatic cancer tumors
Utilized CO2 laser cut/raster and chemical solvent bonding process to produce leakproof platform with standardized channel geometry
Analysis Methods
Place tumor slices in culture chamber and diffuse drug combinations. Add nuclear stain (Hoechst) for fluorescent labeling of delivery regions.
Viability imaging (on/off device) of global slice for drug response analysis
Detailed analysis with parallel or perpendicular cross section (10um) and immunostaining staining.
Results
Results
Fluorescent Analysis for Microfluidic Drug Delivery to Tissue
Successfully characterized device performance with a mixture of Matlab/Python/ImageJ/Excel verifying no-cross talk between drug delivery channels. Diffusion performance is captured at different time points, analysis one-way ANOVA, turkey's multiple comparison test p<0.0001).
Screened drugs on patient cancer tumor samples of glioblastoma (24hr) and metastatic CRC (2 days) to evaluate response to three tested drugs.
Published work in Nature Precision Oncology as "Multiplexed drug testing of tumor slices using a microfluidic platform"
Patient glioblastoma and colorectal tumor drug response on device
Page updated
Google Sites
Report abuse